PDCD1 and cancer: There are at least 11 bsAbs targeting CD19 × CD3, EGFR × MET, gp100 × CD3, CD20 × CD3, BCMA × CD3, CTLA-4 × PD-1, CD20 × CD3, and GPRC5D × CD3, which have been approved for treatment of various cancers.